NCT06544655 2026-04-17
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Active not recruiting
Clinical Trials
518 trialsNCT07405164 2026-04-17
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT02719613 2026-04-15
Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Bristol-Myers Squibb
Phase 2 Completed
NCT03520686 2026-04-15
Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
ImmunityBio, Inc.
Phase 3 Terminated
NCT03661320 2026-04-15
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06946797 2026-04-15
CheckMate-1533
Bristol-Myers Squibb
Phase 2 Recruiting
NCT07518043 2026-04-15
A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07526961 2026-04-14
Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland
Bristol-Myers Squibb
Completed
NCT07527858 2026-04-14
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Gilead Sciences
Phase 2 Not yet recruiting
NCT03686124 2026-04-13
ACTengine
Immatics US, Inc.
Phase 1/2 Recruiting
NCT04895709 2026-04-13
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT05423262 2026-04-13
A Study of TRK-950 in Patients With Advanced Solid Tumors
Toray Industries, Inc
Phase 1/2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06743126 2026-04-13
SUPRAME
Immatics US, Inc.
Phase 3 Recruiting
NCT07392892 2026-04-13
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer
Phase 2/3 Recruiting
NCT07431281 2026-04-13
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04099251 2026-04-09
CheckMate76K
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06101134 2026-04-09
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT07195695 2026-04-08
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Phase 3 Recruiting
NCT01968109 2026-04-06
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03459222 2026-04-06
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04039607 2026-04-06
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT03505320 2026-04-03
ILUSTRO
Astellas Pharma Inc
Phase 2 Active not recruiting
NCT05533697 2026-04-03
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT06504615 2026-04-03
METAGIO
Bristol-Myers Squibb
Active not recruiting
NCT07276373 2026-04-03
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT07476326 2026-04-03
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Biocon Limited
Phase 1 Not yet recruiting
NCT02393625 2026-04-02
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
Novartis
Phase 1 Active not recruiting
NCT04665206 2026-04-02
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
Phase 1/2 Recruiting
NCT05568095 2026-04-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06097728 2026-04-02
eVOLVE-Meso
AstraZeneca
Phase 3 Recruiting
NCT06581406 2026-04-02
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Replimune Inc.
Phase 2/3 Recruiting
NCT07221149 2026-04-02
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT03899155 2026-04-01
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT05267626 2026-03-31
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT06561386 2026-03-31
RELATIVITY1093
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07176975 2026-03-31
A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers
Boehringer Ingelheim
Phase 1 Not yet recruiting
NCT07293351 2026-03-31
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04835805 2026-03-30
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
Phase 1 Active not recruiting
NCT04785820 2026-03-27
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
Hoffmann-La Roche
Phase 2 Completed
NCT05907122 2026-03-27
A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
Amgen
Phase 3 Completed
NCT06948448 2026-03-27
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co. Ltd
Phase 2 Recruiting
NCT07494435 2026-03-27
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Zhejiang Haichang Biotech Co., Ltd.
Phase 2 Not yet recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT04143711 2026-03-18
Study of DF1001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
NCT04423029 2026-03-18
A Study of DF6002 Alone and in Combination With Nivolumab
Dragonfly Therapeutics
Phase 1 Completed